Taken together, these results highlight SORT1, KIF1B, TMEM106B, NPC1, and ATP6V0B as promising diagnostic biomarkers for OM, with SORT1 emerging as the most compelling candidate for future clinical translation. This evidence concerns the gene SORT1 and ocular melanoma.